Chinese Heparin Subject Of U.S. Congress Hearing
This article was originally published in PharmAsia News
The CEO of Baxter International is set to testify before a congressional hearing April 29 on the firm's contaminated heparin from China. Baxter's version of the blood thinner was linked to at least 81 deaths, the problem traced to a single source in China and said to have been deliberate. The title of the House Oversight and Investigations Subcommittee hearing is, "The Heparin Disaster: Chinese Counterfeits and American Failures." Baxter CEO Robert Parkinson and the CEO of the Chinese supplier, Scientific Protein Labs, were on the witness list. (Click here for more
You may also be interested in...
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.
Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.